Calquence approved in Japan for CLL
25 January 2021 07:05 GMT Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia 88% of patients on Calquence remained free of diseaseprogression after 12 months vs. 68% for comparators AstraZeneca's Calquence (acalabrutinib), a next-generation, selective Bruton's tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]). The approval by the Japanese Ministry of Health, Labour and